Molecular Cancer Therapeutics CTRC-AACR San Antonio Breast Cancer Symposium
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Holland, C. M.
Right arrow Articles by Smith, S. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Holland, C. M.
Right arrow Articles by Smith, S. K.
Mol Cancer Ther. 2004;3:993-1001
© 2004 American Association for Cancer Research

Transcriptome analysis of endometrial cancer identifies peroxisome proliferator-activated receptors as potential therapeutic targets

Cathrine M. Holland1,2, Samir A. Saidi2, Amanda L. Evans1, Andrew M. Sharkey1, John A. Latimer2, Robin A.F. Crawford2, D. Stephen Charnock-Jones2, Cristin G. Print1 and Stephen K. Smith1,2

Departments of 1 Pathology and 2 Obstetrics and Gynaecology, University of Cambridge, The Rosie Hospital, Cambridge, United Kingdom

Requests for reprints: Cathrine M. Holland, Department of Obstetrics and Gynaecology, University of Cambridge, The Rosie Hospital, Box 223, Level 2, Robinson Way, Cambridge CB2 2SW, United Kingdom. Phone: 44-1223-336874; Fax: 44-1223-215327. E-mail: cath.holland{at}obgyn.cam.ac.uk

Endometrial cancer is the most common gynecologic malignancy, frequently arising in association with obesity and diabetes mellitus. To identify gene pathways contributing to endometrial cancer development, we studied the transcriptome of 20 endometrial cancers and 11 benign endometrial tissues using cDNA microarrays. Among the transcript changes identified in endometrial cancer were up-regulation of the nuclear hormone receptors peroxisome proliferator-activated receptors (PPAR) {alpha} and {gamma}, whereas retinoid X receptor ß was down-regulated. To clarify the contribution of PPAR{alpha} to endometrial carcinogenesis, we did experiments on cultured endometrial carcinoma cells expressing this transcript. Treatment with fenofibrate, an activating ligand for PPAR{alpha}, significantly reduced proliferation and increased cell death, suggesting that altered expression of nuclear hormone receptors involved with fatty acid metabolism leads to deregulated cellular proliferation and apoptosis. These results support further investigation of members of the PPAR/retinoid X receptor pathway as novel therapeutic targets in endometrial cancer.


Grant support: Medical Research Council Clinical Training Fellowship G84/5733 (C.M. Holland), Medical Research Council Program grant G9623012 (S.K. Smith and D.S. Charnock-Jones), and Raymond and Beverly Sackler Award (C.M. Holland).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 3/30/04; revised 5/ 4/04; accepted 5/14/04.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2004 by the American Association for Cancer Research.